Literature DB >> 19337973

Emerging biological functions of the vaccinia-related kinase (VRK) family.

E P F Klerkx1, P A Lazo, P Askjaer.   

Abstract

The vaccinia-related kinases (VRKs) branched off early from the family of casein kinase (CK) I and compose a relatively uncharacterized family of the kinome. The VRKs were discovered due to their close sequence relation to the vaccinia virus B1R serine/threonine kinase. They were first described in phosphorylation of transcription factors that led to the discovery of an autoregulatory mechanism between VRK and the tumor suppressor transcription factor p53. The relevance of VRKs has broadened recently by introduction of its members as essential regulators in cell signaling, nuclear envelope dynamics, chromatin modifications, apoptosis and cellular stress response. Several phosphorylation substrates have been described, as well as the first positive and negative regulators of VRK. We provide an overview of the VRKs across species and discuss the wide diversity of cellular and organismal requirements for this kinase family.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19337973     DOI: 10.14670/HH-24.749

Source DB:  PubMed          Journal:  Histol Histopathol        ISSN: 0213-3911            Impact factor:   2.303


  29 in total

1.  The nuclear envelope at a glance.

Authors:  Katherine L Wilson; Jason M Berk
Journal:  J Cell Sci       Date:  2010-06-15       Impact factor: 5.285

Review 2.  Viral serine/threonine protein kinases.

Authors:  Thary Jacob; Céline Van den Broeke; Herman W Favoreel
Journal:  J Virol       Date:  2010-11-17       Impact factor: 5.103

3.  VRK2 inhibits mitogen-activated protein kinase signaling and inversely correlates with ErbB2 in human breast cancer.

Authors:  Isabel F Fernández; Sandra Blanco; José Lozano; Pedro A Lazo
Journal:  Mol Cell Biol       Date:  2010-08-02       Impact factor: 4.272

4.  Vaccinia-related kinase 1 (VRK1) is an upstream nucleosomal kinase required for the assembly of 53BP1 foci in response to ionizing radiation-induced DNA damage.

Authors:  Marta Sanz-García; Diana M Monsalve; Ana Sevilla; Pedro A Lazo
Journal:  J Biol Chem       Date:  2012-05-22       Impact factor: 5.157

5.  The changes of vaccinia related kinase 1 in grafted heart after rat heart transplantation.

Authors:  Shiguo Qian; Xuechao Yang; Kunpeng Wu; Qiangsheng Lv; Yuanyuan Zhang; Jiahong Dai; Cheng Chen; Jiahai Shi
Journal:  J Thorac Dis       Date:  2014-12       Impact factor: 2.895

6.  NMR solution structure of human vaccinia-related kinase 1 (VRK1) reveals the C-terminal tail essential for its structural stability and autocatalytic activity.

Authors:  Joon Shin; Goutam Chakraborty; Nagakumar Bharatham; Congbao Kang; Naoya Tochio; Seizo Koshiba; Takanori Kigawa; Wanil Kim; Kyong-Tai Kim; Ho Sup Yoon
Journal:  J Biol Chem       Date:  2011-05-03       Impact factor: 5.157

7.  Mice deficient in the serine/threonine protein kinase VRK1 are infertile due to a progressive loss of spermatogonia.

Authors:  Matthew S Wiebe; R Jeremy Nichols; Tyler P Molitor; Jill K Lindgren; Paula Traktman
Journal:  Biol Reprod       Date:  2009-08-19       Impact factor: 4.285

8.  Spinal muscular atrophy with pontocerebellar hypoplasia is caused by a mutation in the VRK1 gene.

Authors:  Paul Renbaum; Efrat Kellerman; Ranit Jaron; Dan Geiger; Reeval Segel; Ming Lee; Mary Claire King; Ephrat Levy-Lahad
Journal:  Am J Hum Genet       Date:  2009-07-30       Impact factor: 11.025

9.  Human VRK2 (vaccinia-related kinase 2) modulates tumor cell invasion by hyperactivation of NFAT1 and expression of cyclooxygenase-2.

Authors:  Marta Vázquez-Cedeira; Pedro A Lazo
Journal:  J Biol Chem       Date:  2012-10-26       Impact factor: 5.157

10.  Protein kinase VRK-1 regulates cell invasion and EGL-17/FGF signaling in Caenorhabditis elegans.

Authors:  Elke P F Klerkx; Pilar Alarcón; Katherine Waters; Valerie Reinke; Paul W Sternberg; Peter Askjaer
Journal:  Dev Biol       Date:  2009-08-11       Impact factor: 3.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.